7th septiembre 2023
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
(Paris, France – 7 September 2023) – Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution of PYLCLARI™ (INN: Piflufolastat (18F) formerly known as (18F)-DCFPyL), indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography in adults with prostate cancer.
Under the terms of the agreement, b.e. Imaging will be responsible for obtaining marketing authorization from Swiss competent authority Swissmedic, and will have exclusive distribution rights for PYLCLARI™ across Switzerland.
Dr. Michel Wuillemin, Head of Radiopharmaceuticals at b.e. Imaging commented, “b.e. Imaging has proven to be a crucial supplier for the whole range of Curium’s SPECT products for Switzerland. The extension of the partnership with Curium to PSMA PET imaging with PYLCLARI™ underscores b.e. Imaging’s focus in the field of prostate cancer. Curium’s innovative PYLCLARI™ is in line with b.e. Imaging’s experience in the field of radioligand therapy for prostate cancer.”
Benoit Woessmer, PET Europe CEO at Curium commented, “Today’s agreement builds on our existing collaboration with b.e. Imaging, and is an important milestone for prostate cancer patients in Switzerland. Once marketing authorization is obtained, we are extremely pleased to be improving the choice of diagnostic tools available to physicians in Switzerland to better diagnose and monitor prostate cancer – ultimately for the benefit of prostate cancer patients.”
Today’s announcement follows the decision in July 2023 by the European Commission granting marketing authorization for PYLCLARI™ in the European Union. b.e. Imaging currently distributes Curium’s entire suite of SPECT imaging products across Switzerland.
For more information about PYLCLARI™: https://pylclari.eu